{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:26:25Z","timestamp":1785907585991,"version":"3.56.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.msard.2025.106398","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T13:37:05Z","timestamp":1742305025000},"page":"106398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions"],"prefix":"10.1016","volume":"97","author":[{"given":"Christoph","family":"Kleinschnitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Skuljec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus C.","family":"Kowarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Woitschach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Cepek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedicta","family":"K\u00fchnler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylke","family":"Schlemilch-Paschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-9317","authenticated-orcid":false,"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106398_bib0001","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"17_supplement_1","key":"10.1016\/j.msard.2025.106398_bib0002","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1212\/WNL.0000000000205238","article-title":"Prospective longitudinal study of Cladribine Tablets (CLADB Study) demonstrates sustained reduction in kappa free light chains in relapsing multiple sclerosis (RRMS) at 96 weeks (P10-6.008)","volume":"102","author":"Ammoscato","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106398_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108571","article-title":"2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells","volume":"105","author":"Aybar","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2025.106398_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104286","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE Study","volume":"71","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106398_bib0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2025.106398_bib0006","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/1352458510391344","article-title":"Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study","volume":"17","author":"Cook","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106398_bib0007","series-title":"Proceedings of the 2024 CMSC Annual Meeting","article-title":"Effect of cladribine tablets on markers of disease progression, axonal loss, and oligoclonal bands in patients with relapsing multiple sclerosis: results from MAGNIFY-MS","author":"de Stefano","year":"2025"},{"key":"10.1016\/j.msard.2025.106398_bib0008","series-title":"Proceedings of the 8th Congress of the European Academy of Neurology","article-title":"Treatment patterns prior to and post cladribine in patients with multiple sclerosis","author":"Ellenberger","year":"2022"},{"key":"10.1016\/j.msard.2025.106398_bib0009","unstructured":"EMA summary of product charateristics: Mavenclad\u00ae (cladribine tablets). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mavenclad-epar-product-information_en.pdf. (Accessed 22 Jun 2024)."},{"issue":"10","key":"10.1016\/j.msard.2025.106398_bib0010","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease\u2011modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106398_bib0011","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-017-0573-4","article-title":"Cladribine to treat relapsing forms of multiple sclerosis","volume":"14","author":"Giovannoni","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.msard.2025.106398_bib0012","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1007\/s12325-021-01865-w","article-title":"Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets 3.5 mg\/kg for relapsing multiple sclerosis: an exploratory post hoc analysis of the CLARITY and CLARITY extension studies","volume":"38","author":"Giovannoni","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.msard.2025.106398_bib0013","doi-asserted-by":"crossref","DOI":"10.1177\/11795735211060118","article-title":"Humoral immune response and lymphocyte levels after complete vaccination against COVID-19 in a cohort of multiple sclerosis patients treated with cladribine tablets","volume":"13","author":"Grothe","year":"2021","journal-title":"J. Cent. Nerv. Syst. Dis."},{"issue":"1","key":"10.1016\/j.msard.2025.106398_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","article-title":"Treatment with cladribine tablets beyond year 4: a position statement by southeast European multiple sclerosis centers","volume":"12","author":"Habek","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106398_bib0015","series-title":"Investigation of Changes in Lymphocyte Subset Counts and Their Relationship with MRI Outcomes in the MAGNIFY-MS Study","author":"Hodgkinson","year":"2023"},{"key":"10.1016\/j.msard.2025.106398_bib0016","series-title":"Clinical Efficacy of Cladribine Tablets in Patients With Highly Active Relapsing Multiple Sclerosis: 36-Month Interim Results From the Extension Trial to the MAGNIFY-MS Study","author":"Hodgkinson","year":"2024"},{"key":"10.1016\/j.msard.2025.106398_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1327672","article-title":"Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine","volume":"15","author":"Holm Hansen","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106398_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105704","article-title":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - Results from a German cladribine cohort","volume":"88","author":"Kowarik","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106398_bib0019","unstructured":"Krankheitsbezogenes Kompetenznetz Multiple Sklerose, 2024: Qualit\u00e4tshandbuch MS \/NMOSD \/ MOGAD. https:\/\/ms-qualitaetshandbuch.de\/. (Accessed 25 June 2024)."},{"key":"10.1016\/j.msard.2025.106398_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577966","article-title":"Cladribine treatment for highly active multiple sclerosis: real-world clinical outcomes for years 3 and 4","volume":"372","author":"Magalashvili","year":"2022","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106398_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343892","article-title":"CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis","volume":"15","author":"Marastoni","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106398_bib0022","unstructured":"Maynard, M., Bass, J., Salter, A., Hernandez, R.S., Hooshmand, S., Obeidat, A. Prior disease-modifying therapy influence on lymphocyte dynamics after treatment with oral cladribine in multiple sclerosis. Presented at ACTRIMS 2024 [P147]."},{"issue":"4","key":"10.1016\/j.msard.2025.106398_bib0023","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s40120-022-00394-0","article-title":"Expert-agreed practical recommendations on the use of cladribine","volume":"11","author":"Meca-Lallana","year":"2022","journal-title":"Neurol. Ther."},{"issue":"13","key":"10.1016\/j.msard.2025.106398_bib0024","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert. Opin. PharmacOther"},{"issue":"2","key":"10.1016\/j.msard.2025.106398_bib0025","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4132\/jptm.2023.02.23","article-title":"Aneurysmal bone cyst: a review","volume":"57","author":"Nasri","year":"2023","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.msard.2025.106398_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106398_bib0027","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"issue":"21","key":"10.1016\/j.msard.2025.106398_bib0028","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10215207","article-title":"Long-term safety and efficacy of subcutaneous cladribine used in increased dosage in patients with relapsing multiple sclerosis: 20-year observational study","volume":"10","author":"Rejdak","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2025.106398_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103931","article-title":"Immunological consequences of cladribine treatment in multiple sclerosis: a real-world study","volume":"64","author":"Rolfes","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"10.1016\/j.msard.2025.106398_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/cells12091243","article-title":"Immune response to seasonal influenza vaccination in multiple sclerosis patients receiving cladribine","volume":"12","author":"Rolfes","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.msard.2025.106398_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1133967","article-title":"Cladribine treatment specifically affects peripheral blood memory B cell clones and clonal expansion in multiple sclerosis patients","volume":"14","author":"Ruschil","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106398_bib0032","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231211077","article-title":"Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response","volume":"16","author":"Teschner","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106398_bib0033","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200048","article-title":"Specific patterns of immune cell dynamics may explain the early onset and prolonged efficacy of cladribine tablets: a MAGNIFY-MS substudy","volume":"10","author":"Wiendl","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106398_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105812","article-title":"Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: final results of the non-interventional study CLEVER","volume":"90","author":"Ziemssen","year":"2024","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825001403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:40:35Z","timestamp":1762602035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825001403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":34,"alternative-id":["S2211034825001403"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106398","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106398"}}